News Roche hails 4 year NICE access deal for Gazyvaro NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the dru
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
